Asylia Diagnostics -
Diagnostics Technology Platform for Immuno-Oncology

Andrey Khmelevskiy, CEO
Asylia Diagnostics BV - JLabs (JnJ) resident
Turnhoutseweg 30, 2340 Beerse,
Belgium

Problem

1 out of 6 immunotherapy patients
are at risk of hyperprogressive disease (HPD)




Cancer patient
No Diagnostics Test
Immunotherapy
85%
NO extra $ + Life
15% HPD
EXTRA $ + Life
Today
Asylia's Diagnostics Test
Immunotherapy
85%
NO extra $ + Life
15% HPD
Alternative therapy
~ 100K $ SAVINGS + Life
Tomorrow
Solution
Asylia's portfolio of molecular diagnostics tests for predicting hyperprogressive disease in solid tumors

Asylia’s Technology

Asylia’s AI powered intelligent platform and knowledge base for discovery and development of molecular biomarkers for predicting risk of hyperprogression for all solid tumors targeted by immunotherapy (ICB). Our technology translates biomarkers into qPCR diagnostics assays that can be integrated to platforms such as Biocartis, ThermoFisher, Illumina.

Asylia’s has developed predictive biomarker signatures for melanoma and NSCLC cancers based on RNA expression of 14 genes with accuracy of 78% that has worldwide FTO and IP for melanoma and NSCLC filled.

Technology Competitive Advantages

- Technology (qPCR) is simple and non-disruptive to clinical care to be widely accessible in the clinic
- Technology is scalable to multiple cancer subtypes
- Technology can be sold as a stand-alone kit or integrated IVD platforms
- Technology has potential become both CDx or complementary Dx

Asylia's Go-To-Market Path and Assay Pipeline

Asylia has an LOI from global IVD company and an LOI from the US-based pharma company

Current stage of Asylia Diagnostics



Biomarker assay discovery

Validation of the biomarker assay

Integration of the assay into device

Research-only use test sales

Clinical trial for clinical use test

Pre-revenue stages

Asylia's tests provide:

- Better outcomes
- Saves **$100'000** per HPD patient
- Targeted patient selection for clinical trials

Market opportunity:

- **100'350 melanoma** patients per year
- **228'000 lung** patients per year
- Clinical **trials 2250** globally

$5'000 per test



Asylia's Partnering and Financing Opportunities

We are looking for:

- Partnering with biotech/pharma with PD-1/PD-L1/CTLA-4 candidates for solid tumors on exploratory biomarker activities (identification of super-responders subpopulations) and MDx/CDx co-development
- Collaborations with KOLs in the US and EU to further expand our clinical study sites
- Funding of 600K EUR to cover costs of the current assay validation stage

Reach out to:

Andrey Khmelevskiy, CEO
Asylia Diagnostics BV
Turnhoutseweg 30, 2340 Beerse, Belgium
andrey.khmelevskiy@asyliadx.com
www.asyliadx.com
+31 627483736